H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Adlai Nortye (ANL) to $20 from $16 and keeps a Buy rating on the shares. The company’s lead asset, AN9025, demonstrates “potential best-in-class potency” (250-fold to in preclinical models, positioning it as differentiated next-generation small molecule pan-RAS(ON) inhibitor, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANL:
- Adlai Nortye Raises $150 Million in Oversubscribed Private Placement to Advance Cancer Pipeline
- Adlai Nortye Ltd (ADR) trading resumes
- Adlai Nortye Ltd (ADR) trading halted, volatility trading pause
- Adlai Nortye Reshapes Top Leadership as President Retires and R&D Chief Steps Up
- Leerink bullish on Adlai Nortye, initiates with an Outperform